Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists

Movement Disorders

Volumn 19, Issue 6, 2004, Pages 656-662

  Horvath, Judit ^a   Fross, Robin D ^b   Kleiner Fisman, Galit ^c   Lerch, René ^a   Stalder, Hans ^a   Liaudat, Suzanne ^a   Raskoff, William J ^b   Flachsbart, Keith D ^b   Rakowski, Harry ^c   Pache, Jean Claude ^a   Burkhard, Pierre R ^a   Lang, Anthony E ^c  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Agonists; Cabergoline; Ergot derived dopamine; Heart; Parkinson's disease; Pergolide; Valvulopathy

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANOREXIGENIC AGENT; ANTICOAGULANT AGENT; ANTIMIGRAINE AGENT; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; DEXFENFLURAMINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ERGOT ALKALOID; ERGOT DERIVATIVE; ERGOTAMINE; FENFLURAMINE; FUROSEMIDE; METHYSERGIDE; PERGOLIDE; PRAMIPEXOLE; SELEGILINE; SEROTONIN 2B RECEPTOR; VERAPAMIL;

ADULT; AGED; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; DYSKINESIA; DYSPNEA; ECHOCARDIOGRAPHY; ENDOCRINE DISEASE; FEMALE; FIBROGENESIS; HALLUCINATION; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART MURMUR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MEDICAL LITERATURE; PALLIDOTOMY; PARKINSON DISEASE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTLESS LEGS SYNDROME; VALVULAR HEART DISEASE;

ADULT; AGED; CARBIDOPA; DOPAMINE AGONISTS; DRUG COMBINATIONS; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; ERGOLINES; ERGOT ALKALOIDS; FEMALE; HEART VALVE DISEASES; HUMANS; LEVODOPA; MALE; PARKINSON DISEASE; PERGOLIDE;

EID: 4444351812     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20201     Document Type: Article

References (17)

1. Ling LH, Ahlskog JE, Munger TM, et al. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist (cabergoline) for Parkinson's disease. Mayo Clin Proc 1999;74: 371-375.
2. Todman DH, Oliver WA, Edwards RL. Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease. Clin Exp Neurol 1990;27:79-82.
3. Danoff SK, Grasso ME, Terry PB, Flynn JM. Pleuropulmonary disease due to pergolide use for restless legs syndrome. Chest 2001;120:313-316.
4. Kastelik JA, Aziz I, Greenstone MA, Thompson R, Morice AH. Pergolide-induced lung disease in patients with Parkinson's disease. Respir Med 2002;96:548-550.
5. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-588.
6. Flaherty KR, Bates JR. Mitral regurgitation caused by chronic ergotamine use. Am Heart J 1996;131:603-606.
7. Redfield M, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992;117:50-52.
8. Wilke A, Hesse H, Hufnagel G, Maisch B. Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine. Eur Heart J 1997;18:701.
9. Botero M, Fuchs R, Paulus DA. Carcinoid heart disease: a case report and literature review. J Clin Anesth 2002;14:57-63.
10. Serratrice J, Disdier P, Habib G, Viallet F, Weiller P. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 2002;10:334-336.
11. Pritchett AM, Morrison JF, Edwards WD, et al. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002;77: 1280-1286.
12. Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003;61:859-861.
13. Hensrud DD, Connolly HM, Grogan M, et al. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc 1999;74:1191-1197.
14. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000;57:75-81.
15. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836-2841.
16. Milian MJ, Maiofiss L. Cussac D, Audinot V, Boutin J, Newman-Tancredi A. Differential actions of antiparkinsonian agents at multiple classes of monoaminergic receptors. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002;303:791-804.
17. Flowers CM, Racoosin JA, Lu AL, Beitz JG. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 2003;78:730-731.